At a glance
ClinicalIndex Comparison RecordN/ACompleted· 76 enrolled
Drug / intervention
Baerveldt 350 implant +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Baerveldt Versus ClearPath Comparison Study
In Brief
A clinical study evaluating Baerveldt 350 implant and Ahmed ClearPath 350 implant for Glaucoma. Completed, enrolled 76 participants across 1 site.
Detailed Summary
This is a randomized prospective study of post-operative surgical outcomes and complication rates in patients with a Baerveldt 350 implant vs the Ahmed ClearPath implant. Each subject will be randomized to the Baerveldt group or ClearPath group at the time of consent for the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartDec 2020
Primary CompletionJun 2023
TodayJul 2026
First PostedJul 13, 2020
Enrollment StartDec 17, 2020
Primary CompletionJun 29, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 6.0 years ago
Interventions
Baerveldt 350 implantdevice
The Baerveldt implant is an FDA-approved silicone, non-valved implant.
Ahmed ClearPath 350 implantdevice
The Ahmed ClearPath is a non-valved glaucoma drainage device.